AngioDynamics (ANGO) CEO James Clemmer Receives 52,358 Shares

What Happened
James C. Clemmer, President, CEO and Director of AngioDynamics (ANGO), received 52,358 shares of common stock on July 22, 2026 upon settlement of performance share units (no cash exercise price). To satisfy tax withholding, 26,728 of those shares were surrendered at $13.82 per share for a withholding value of $369,381. The reporting notes that the original target grant was 184,361 performance share units; only 52,358 shares were earned and issued and the remaining target units were forfeited (not sold). Net shares acquired by Clemmer from this settlement: 25,630.

Key Details

• Transaction date: July 22, 2026; Form 4 filed July 24, 2026 (timely).
• Issued/vested: 52,358 shares (derivative settlement, code M) at $0.00 exercise price.
• Tax withholding: 26,728 shares disposed (code F) at $13.82 for $369,381 withheld.
• Forfeiture/cancellation: 184,361 target performance units reflected as not issued/forfeited per footnote.
• Shares owned after transaction: not specified in the provided excerpt.
• Footnotes: F1–F3 explain settlement of a July 19, 2023 PSU grant with performance-based vesting (0–200% payout and a possible ± adjustment based on relative TSR).

Context: These shares result from a performance-based award vesting and a routine share-withholding to cover taxes — not an open-market purchase or sale. Derivative code M indicates conversion/settlement of PSUs; code F indicates shares surrendered for tax withholding. Such compensation settlements are common and reflect award payout and tax mechanics rather than an explicit market view by the insider.